Last reviewed · How we verify
Psychotropic medication optimization
Psychotropic medication optimization is a clinical service/program that systematically adjusts psychiatric medications to improve efficacy and tolerability for individual patients.
Psychotropic medication optimization is a clinical service/program that systematically adjusts psychiatric medications to improve efficacy and tolerability for individual patients. Used for Optimization of antidepressant, antipsychotic, and mood stabilizer therapy in patients with treatment-resistant or suboptimal response to psychotropic medications.
At a glance
| Generic name | Psychotropic medication optimization |
|---|---|
| Also known as | SSRI, SNRI, Benzodiazepine, |
| Sponsor | University of Washington |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
This is not a single drug entity but rather a therapeutic approach or clinical program, typically involving pharmacogenomic testing, dose adjustment, and medication selection optimization for patients on psychotropic agents. It aims to personalize treatment by matching medications to individual patient factors including genetics, comorbidities, and prior response history.
Approved indications
- Optimization of antidepressant, antipsychotic, and mood stabilizer therapy in patients with treatment-resistant or suboptimal response to psychotropic medications
Common side effects
Key clinical trials
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (PHASE3)
- Impact of "ASAP" Multidisciplinary Optimization Care Protocol on Clinical Outcome in Elderly Inpatients for Hip Fracture
- Optimization of Deprescribing Antidepressants in Nursing Home Residents With Dementia (NA)
- Primary Care Intervention Strategy for Anxiety Disorders (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psychotropic medication optimization CI brief — competitive landscape report
- Psychotropic medication optimization updates RSS · CI watch RSS
- University of Washington portfolio CI